RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Understanding the patient-perceived impact of nonalcoholic steatohepatitis
Raising the volume on a silent disease
Doward, L., Balp, M-M., Twiss, J., Slota, C., Cryer, D., Langford, A., Collen, R., Agashivala, N., Brass, CA., Anstee, QM., & Sanyal, AJ. (2017). Understanding the patient-perceived impact of nonalcoholic steatohepatitis: Raising the volume on a silent disease. Hepatology, 66(Suppl 1), 1182A. Article 2232. https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.29501
Background Nonalcoholic steatohepatitis (NASH), a progressive form of fatty liver disease is often considered a ‘silent’ disease in its early stages. As there are limited data on the lived-experience of NASH the aim was to explore the patient-perspective of living with NASH.
Methods Semi-structured, face-to-face, concept elicitation (CE) interviews were conducted with NASH patients recruited via a tertiary care centre in VA, USA. The interviews explored patients’ experiences of NASH symptoms and the impact of NASH on the way patients feel and function. Interviews were audio-recorded, transcribed and analysed thematically. Patients completed a sociodemographic questionnaire. Medical data were extracted from patient charts.
Results 23 NASH patients were interviewed (females=18[78%]; %]; mean age =55.9[31.0-73.0 yrs]): 16 (69.6%) had biopsy-diagnosed NASH (F1=1[4.3%]; F2=5[21.7%]; F3=10[43.5%]), 7 (30.4%) had phenotypic-diagnosed NASH. Mean (SD) years since diagnosis=3.9(2.9). None had evidence of hepatic decompensation. Patients were overweight/obese (mean BMI = 34.8 [range 26.1-45.0]). Common comorbidities included hypertension (n=15;65.2%), high cholesterol (n=11;47.8%) and T2DM (n=14;60.9%). Key symptoms reported included pain in upper right quadrant (abdomen) (n=14; 60.9%), fatigue (n=18; 78.3%), poor sleep quality (n=12; 52.2%), cognition problems (impaired memory [n=13; 56.5%]; reduced ability to focus / concentrate on tasks [n=11; 47.8%] and pruritus [n=10; 43.5%]). Symptoms were reported to impact on physical functioning (impaired capacity to walk short distances) and ability to conduct daily living tasks e.g. household chores/personal care. NASH impacted the quality of family relationships; e.g. pain and fatigue reduced patient’s ability to play with children/grandchildren or limited engagement in family life. Patients also reported a negative impact on physical/emotional aspects of intimate relationships. Patients reported hiding their symptoms to reduce worry for family members. Relationships with friends were affected; patients felt less able/willing to participate in social activities. Some patients worried about perceived NASH-related stigma and/or reported self-consciousness related to body shape/appearance. Anxiety and low mood were also reported. For the 10 (43.5%) patients in employment, NASH impacted ability to concentrate on or complete work-related tasks. Conclusions The interviews identified key symptoms experienced by NASH patients and the impact of NASH on patient health-related quality of life. These data challenge the dogma that NASH is an asymptomatic condition and support future patient-centred research initiatives in NASH.